02 February 2011

Professor Paul Kenny of the Institute says, "These findings point to a promising target for the development of potential anti–smoking therapies." The study specifically focused on the chemical alpha–5 in a brain pathway known as the habenulo–interpeduncular tract.
Co–researcher Christie Fowler says, "It was unexpected that the habenula, and brain structures into which it projects, play such a profound role in controlling the desire to consume nicotine. The habenula appears to be activated by nicotine when consumption of the drug has reached an adverse level. But if the pathway isn’t functioning properly, you simply take more." She said the data could explain why some people are far more vulnerable to the addictive properties of nicotine and more likely to develop smoking–associated diseases such as lung cancer.
Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.